Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias

Selective targeting of BCL-2 with the BH3-mimetic venetoclax has been a transformative treatment for patients with various leukemias. TP-53 controls apoptosis upstream of where BCL-2 and its prosurvival relatives, such as MCL-1, act. Therefore, targeting these prosurvival proteins could trigger apop...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood
Main Authors: Thijssen, Rachel, Diepstraten, Sarah T., Moujalled, Donia, Chew, Edward, Flensburg, Christoffer, Shi, Melissa X., Dengler, Michael A., Litalien, Veronique, MacRaild, Sarah, Chen, Maoshan, Anstee, Natasha S., Reljić, Boris, Gabriel, Sarah S., Djajawi, Tirta M., Riffkin, Chris D., Aubrey, Brandon J., Chang, Catherine, Tai, Lin, Xu, Zhen, Morley, Thomas, Pomilio, Giovanna, Bruedigam, Claudia, Kallies, Axel, Stroud, David A., Bajel, Ashish, Kluck, Ruth M., Lane, Steven W., Schoumacher, Marie, Banquet, Sébastien, Majewski, Ian J., Strasser, Andreas, Roberts, Andrew W., Huang, David C. S., Brown, Fiona C., Kelly, Gemma L., Wei, Andrew H.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2021
Assuntos:
Plenary Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8138548/
https://ncbi.nlm.nih.gov/pubmed/33824975
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020010167
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares